Pharma IQ Glossary: Amorphous Materials
Amorphous Materials, also known as soft glasses, deform and flow through a collective movement of their particles. These materials (which include chocolate mousse, shaving cream, mayonnaise, metallic glasses, granular materials and mud) are amorphous solids, in other words, they are resistant like solids but, like liquids, lack a crystalline structure. Colloids, emulsions, window glass, dense polymers, and even biological tissues are some examples.
World’s First Artificial Enzymes Created Using Synthetic Biology
December 04 by Pharma IQ NewsMedical Research Council (MRC) scientists have created the world’s first enzymes made from artificial genetic material. Their synthetic enzymes, which are made from molecules that do not occur anywher...
Pathogen Safety: Raw Materials - A Pathogen or Viral Threat?
September 10 by Andrea CharlesImplementing effective pathogen safety strategies is essential for preventing contamination and ensuring the safety of your biologics. Raw materials can bring a pathogen or virus into your manufacturi...
Survey: Improving Solubility 2012
April 27 by Pharma IQ SurveysIn preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions...
Ensuring Stability the Biggest Amorphous Challenge for 88.2% of Developers
July 27 by Pharma IQThe use of amorphous pharmaceutical materials is widely considered an effective way of improving favourable drug properties and the latest findings from Pharma IQ suggest that many developers consider...
Spray-Dried Dispersion Technology: Solving Drug Solubility Challenges
March 09 by Amber ScorahAmorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules. Methods for formulating and predicting the physical stabilit...
Implementing Thermal Processing Technologies for the Production of Amorphous Solid Dispersions
September 05 by Helen WinsorAmorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development. Dr. Dave Miller, Senior Principal Scientist at Hoffmann-La Roche, speaks to...
The Challenges of Amorphous Solid Dispersion Production: A Hoffman La Roche Perspective
July 11 by Pharma IQDr. Dave Miller, Senior Principal Scientist at Hoffmann La Roche, shares his views on how to optimise amorphous form selection, techniques to enhance amorphous drug performance and the best strategies...
Be Prepared for Scale Up of Co-crystal Production
July 06 by Vaibhav SihorkarDr. Vaibhav Sihorkar, Head of Pharmaceutical Development at Aurigene Discovery Technologies in India, gave Pharma IQ his insights on existing challenges to co-crystal commercialisation. Wha...
Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK
June 11 by Pharmaceuticals & Biotechnology EditorDrug Discovery and the Market Today Part 4: Developing Amorphous Forms
June 11 by Pharmaceuticals & Biotechnology EditorAmorphous Material Studies: Collaboration, Commitment and Compliance
January 03 by Marc DescampsMarc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Pharma IQ to discuss the use of amorphous pha...
Predicting Physical Stability of Amorphous Solid Dispersions
January 03 by Stephanie GrecoStéphanie Greco, Analyst Scientist, Pharmaceutical Science Department, Sanofi-aventis, joined Pharma IQ to discuss predicting physical stability of amorphous solid dispersions. Pharma IQ: Please...
